HLS Therapeutics Inc
74D
Company Profile
Business description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
Contact
10 Carlson Court
Suite 701
EtobicokeONM9W 6L2
CANT: +1 647 495-9000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
92
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,209.10 | 28.30 | 0.31% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 27,093.72 | 170.10 | 0.63% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,855.64 | 254.86 | -0.47% |
| NZX 50 Index | 13,743.57 | 83.78 | 0.61% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,883.90 | 28.10 | 0.32% |
| SSE Composite Index | 4,131.76 | 19.16 | 0.47% |